Compare KKR & Co Inc (KKR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Neurocrine Biosciences Inc — how do they compare? KKR & Co Inc trades at $91.07 (market cap $80.39B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: KKR & Co Inc is far larger — about 5.6× Neurocrine Biosciences Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KKR | NBIX | |
|---|---|---|
Market Cap | $80.39B | $14.36B |
Volume | 6,517,705 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $142.75 | $185.50 |
52-Week Low | $83.88 | $123.10 |
Typical Hold Time | 67 Days | 23 Days |
Enterprise Value | $2.95B | $14.37B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $90.95, up 1.43% on the day, with strong analyst support showing 24 buy ratings and a $123.30 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Technical indicators are bearish overall, with RSI levels suggesting potential oversold conditions. The company maintains solid profitability with 14.97% net income margin and continues active portfolio management through recent acquisitions and divestitures.
The investment case for KKR appears favorable given the significant upside to analyst targets and strong institutional support. However, investors face risks from volatile cash flows, high debt levels, and market-sensitive revenue streams. The upcoming Q3 2026 earnings report on November 9 will be crucial for validating current valuation metrics.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
